Autism Spectrum Disorder

Neurology·MeSH: Autism Spectrum Disorder

Prevalence

0.1 / 100K

14 drugs in development·10 companies·33 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
folinic acid	GH Research PLC (GHRS)
GWP42003-P	Jazz Pharmaceuticals plc (JAZZ)
KarX-EC	BRISTOL MYERS SQUIBB CO (BMY)

Phase 2(8)

Drug	Company
Cannabidivarin	UNITED THERAPEUTICS Corp (UTHR)
dt402	Definium Therapeutics Inc. (DFTX)
dt402 (r-enantiomer of 3	Definium Therapeutics Inc. (DFTX)
gwp42006	GW PHARMACEUTICALS PLC (GWPH)
Intranasal Oxytocin	UNITED THERAPEUTICS Corp (UTHR)
ml-004/	MapLight Therapeutics, Inc. (MPLT)
MM402	Definium Therapeutics Inc. (DFTX)
pax-101	Kuvatris Therapeutics, Inc. (PXMD)

Preclinical(1)

Drug	Company
fin-211	Finch Therapeutics Group, Inc. (FNCH)

Phase 4(2)

Drug	Company
Cannabidivarin	Jazz Pharmaceuticals plc (JAZZ)
Gabapentin	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 14 drugs in development for Autism Spectrum Disorder across 10 companies.

There are 33 clinical trials targeting Autism Spectrum Disorder tracked by BioSniper.

The estimated prevalence of Autism Spectrum Disorder is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.